140 related articles for article (PubMed ID: 20373861)
1. Mitochondrial Hsp90 chaperones as novel molecular targets in prostate cancer.
Altieri DC
Future Oncol; 2010 Apr; 6(4):487-9. PubMed ID: 20373861
[No Abstract] [Full Text] [Related]
2. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
[TBL] [Abstract][Full Text] [Related]
3. Compartmentalized cancer drug discovery targeting mitochondrial Hsp90 chaperones.
Kang BH; Altieri DC
Oncogene; 2009 Oct; 28(42):3681-8. PubMed ID: 19648961
[TBL] [Abstract][Full Text] [Related]
4. Advances in the role of heat shock protein 90 in prostate cancer.
Fu Z; Jia B
Andrologia; 2022 May; 54(4):e14376. PubMed ID: 35075667
[TBL] [Abstract][Full Text] [Related]
5. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer.
Leav I; Plescia J; Goel HL; Li J; Jiang Z; Cohen RJ; Languino LR; Altieri DC
Am J Pathol; 2010 Jan; 176(1):393-401. PubMed ID: 19948822
[TBL] [Abstract][Full Text] [Related]
6. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.
Moses MA; Henry EC; Ricke WA; Gasiewicz TA
Cancer Prev Res (Phila); 2015 Mar; 8(3):249-57. PubMed ID: 25604133
[TBL] [Abstract][Full Text] [Related]
7. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
Lin Z; Peng R; Li Z; Wang Y; Lu C; Shen Y; Wang J; Shi G
Int J Mol Med; 2015 Aug; 36(2):424-32. PubMed ID: 26059743
[TBL] [Abstract][Full Text] [Related]
8. The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer.
Ischia J; Saad F; Gleave M
Curr Opin Urol; 2013 May; 23(3):194-200. PubMed ID: 23385973
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
Siegelin MD
Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
[TBL] [Abstract][Full Text] [Related]
10. 2,4-dihydroxy benzaldehyde derived Schiff bases as small molecule Hsp90 inhibitors: rational identification of a new anticancer lead.
Dutta Gupta S; Revathi B; Mazaira GI; Galigniana MD; Subrahmanyam CV; Gowrishankar NL; Raghavendra NM
Bioorg Chem; 2015 Apr; 59():97-105. PubMed ID: 25727264
[TBL] [Abstract][Full Text] [Related]
11. Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.
Chen L; Li J; Farah E; Sarkar S; Ahmad N; Gupta S; Larner J; Liu X
Mol Cancer Ther; 2016 Sep; 15(9):2107-18. PubMed ID: 27390342
[TBL] [Abstract][Full Text] [Related]
12. HSP90 Molecular Chaperones, Metabolic Rewiring, and Epigenetics: Impact on Tumor Progression and Perspective for Anticancer Therapy.
Condelli V; Crispo F; Pietrafesa M; Lettini G; Matassa DS; Esposito F; Landriscina M; Maddalena F
Cells; 2019 Jun; 8(6):. PubMed ID: 31163702
[TBL] [Abstract][Full Text] [Related]
13. TRAP1 regulation of mitochondrial life or death decision in cancer cells and mitochondria-targeted TRAP1 inhibitors.
Kang BH
BMB Rep; 2012 Jan; 45(1):1-6. PubMed ID: 22281005
[TBL] [Abstract][Full Text] [Related]
14. HSP90 and Co-chaperones: Impact on Tumor Progression and Prospects for Molecular-Targeted Cancer Therapy.
Jafari A; Rezaei-Tavirani M; Farhadihosseinabadi B; Taranejoo S; Zali H
Cancer Invest; 2020 May; 38(5):310-328. PubMed ID: 32274949
[TBL] [Abstract][Full Text] [Related]
15. Cell Stress Induced Stressome Release Including Damaged Membrane Vesicles and Extracellular HSP90 by Prostate Cancer Cells.
Eguchi T; Sogawa C; Ono K; Matsumoto M; Tran MT; Okusha Y; Lang BJ; Okamoto K; Calderwood SK
Cells; 2020 Mar; 9(3):. PubMed ID: 32204513
[TBL] [Abstract][Full Text] [Related]
16. Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells.
Nepali K; Lin MH; Chao MW; Peng SJ; Hsu KC; Eight Lin T; Chen MC; Lai MJ; Pan SL; Liou JP
Bioorg Chem; 2019 Oct; 91():103119. PubMed ID: 31349117
[TBL] [Abstract][Full Text] [Related]
17. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
Dutta Gupta S; Bommaka MK; Banerjee A
Eur J Med Chem; 2019 Sep; 178():48-63. PubMed ID: 31176095
[TBL] [Abstract][Full Text] [Related]
18. Rational Identification of Hsp90 Inhibitors as Anticancer Lead Molecules by Structure Based Drug Designing Approach.
Gupta SD; Swapanthi PS; Bhagya D; Federicci F; Mazaira GI; Galigniana MD; Subrahmanyam CVS; Gowrishankar NL; Raghavendra NM
Anticancer Agents Med Chem; 2020; 20(3):369-385. PubMed ID: 31713499
[TBL] [Abstract][Full Text] [Related]
19. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
Bickel D; Gohlke H
Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
[TBL] [Abstract][Full Text] [Related]
20. HSP90 inhibitors as therapy for multiple myeloma.
Usmani SZ; Chiosis G
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S77-81. PubMed ID: 22035754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
